Cost Effectivie Analysis (CEA) Pengobatan Tunggal dan Kombinasi pada Pasien Tuberkulosis Paru di RSUD dr. La Palaloi Kabupaten Maros

Authors

  • Ira Widya Sari Program Studi DIII Farmasi, Institut Ilmu Kesehatan Pelamonia
  • Yani Pratiwi Program Studi DIII Farmasi, Institut Ilmu Kesehatan Pelamonia
  • Irfan Kurniawan Universitas Negeri Makassar
  • A.Aulia Salsabila Program Studi DIII Farmasi, Institut Ilmu Kesehatan Pelamonia

DOI:

https://doi.org/10.57214/jka.v9i2.976

Keywords:

Combination Therapy, Cost Effectiveness Analysis, Pharmacoeconomics, Pulmonary Tuberculosis, Single Therapy

Abstract

TB treatment requires long-term therapy using anti-tuberculosis drugs (OTAs), either singly or in combination. The use of combination therapy is considered more effective in preventing drug resistance and increasing treatment success. However, the choice of therapy method is also influenced by economic considerations, considering the continuing increase in health care costs. Therefore, a pharmacoeconomic analysis is needed, specifically a Cost Effectiveness Analysis (CEA) to compare the costs and effectiveness of two treatment alternatives, namely single OAT therapy and combination therapy. Cost Effectiveness Analysis (CEA) is a type of pharmacoeconomic analysis in which all costs are compared with the effects of two or more treatment options. Single OAT treatment is a medical action undertaken by tuberculosis patients, while combination treatment is a treatment method consisting of two or more drugs or treatment techniques used simultaneously to increase treatment effectiveness, reduce the risk of resistance, or improve clinical outcomes. The research method is a descriptive non-experimental, the data studied are retrospective using secondary data from patient medical records. The results showed that treatment of pulmonary tuberculosis using combination therapy (rifampicin and isoniazid) is more cost-effective with an ACER value of Rp132. 182 compared to single therapy (ethambutol) with an ACER value of Rp. 170,536 and an ICER value of combination and single therapy of Rp. 119,857.

References

Dhaniaputri, A., & Arini, M. (2024). Unveiling quality, clinical, and financial impacts of pulmonary tuberculosis clinical pathway implementation in Magelang Public Hospital, Indonesia. Journal of Public Health and Development, 22(1), 268–282. https://doi.org/10.55131/jphd/2024/220120

Irawan, T., & Wahyuningsih. (2023). Strategy to reduce the incidence of pulmonary tuberculosis (TB) through spatial analysis and literacy studies in Batang Regency, Indonesia. Open Access Indonesian Journal of Medical Reviews, 3(5), 492–497. https://doi.org/10.37275/oaijmr.v3i5.363

Islam, Z., Hastuti, S., & Mansur, R. R. (2023). Analisis efektivitas biaya penggunaan cefiksim dan ceftriakson pada pasien pneumonia. Majalah Farmasi dan Farmakologi, 27(3), 11–14. https://doi.org/10.20956/mff.SpecialIssue

Issaura, I., Azizah, N. F., Faizah, R. N., Jami’atusholihah, I. P., & Rahmania, S. N. (2022). Analisis farmakoekonomi (cost effectiveness analysis) penggunaan terapi infus imunoglobulin intravena (IVIG) pada kasus Coronavirus disease (COVID-19). Majalah Farmaseutik, 18(1), 90. https://doi.org/10.22146/farmaseutik.v18i1.71903

Jusma, Suarnianti, & Abrar, E. A. (2024). Hubungan information seeking terhadap treatment seeking behaviour pada individu yang menderita TB paru di wilayah kerja Puskesmas Pacerakkang. Indonesian Journal of Nursing & Health Care, 1(1), 17–20. https://doi.org/10.64914/6fazhv71

Kafie, C., et al. (2024). Cost and cost-effectiveness of digital technologies for TB adherence support. BMJ Global Health, 9(10), e015654. https://doi.org/10.1136/bmjgh-2024-015654

Kementerian Kesehatan Republik Indonesia. (2024). Update kasus tuberkulosis di Indonesia: Kemenkes capai 81 persen dari target deteksi 2024. Kompas.com. https://health.kompas.com/read/25C24180000668/update-kasus-tuberkulosis-di-indonesia--kemenkes-capai-81-persen-dari-target

Min, S., et al. (2024). Cost-effectiveness of improving patients’ adherence to TB treatment through the current TB program. Public Health Journal. https://www.sciencedirect.com/science/article/pii/S1876034124000030

Pratiwi, A., Pramono, A., & Junaedi, E. (2020). Socio-economic and environmental risk factors of tuberculosis in Wonosobo, Central Java, Indonesia. Jurnal Kesehatan Masyarakat (KEMAS), 16(2), 148–157. https://doi.org/10.15294/kemas.v16i1.12636

Puput, D., & Arum, P. (2024). Analisis efektivitas biaya pengobatan pasien tuberkulosis paru di RSUD Banyumas tahun 2022. STIKes Ibnu Sina Ajibarang Journal, 1(1).

Relationship between household tuberculosis and socioeconomic factors. (2025). International Journal of Community Medicine, 10(7), 119–124. https://journals.lww.com/ijcm/fulltext/2025/07000/relationship_between_household_tuberculosis_and.24.aspx

Rismayanti, M. A. N., Ansariadi, A., & Devana, A. T. (2023). Analisis determinan tuberculosis di Kota Makassar. Media Publikasi Promosi Kesehatan Indonesia (MPPKI), 6(2), 290–295. https://doi.org/10.56338/mppki.v6i2.3038

Sari, M. (2021). Terapi tuberkulosis. Jurnal Medika Hutama, 3(1), 1571–1575.

Sinaga, A., & Berutu, A. (2022). Analisis efektivitas biaya (CEA) pengobatan kombinasi dan OAT pada pasien tuberkulosis paru di Rumah Sakit Umum Imelda Pekerja Indonesia Medan. Jurnal Ilmiah Farmasi Imelda (JIFI), 6(1), 36–43. https://doi.org/10.52943/jifarmasi.v6i1.1113

Soeroso, N. N., Siahaan, L., Khairunnisa, S., Anggriani, R. A. H., Aida, A., Eyanoer, P. C., Daulay, E. R., Burhan, E., Rozaliyani, A., Ronny, R., et al. (2024). The association of chronic pulmonary aspergillosis and chronic pulmonary histoplasmosis with MDR-TB patients in Indonesia. Journal of Fungi, 10(8), 529. https://doi.org/10.3390/jof10080529

Sukirawati. (2020). Partisipasi keluarga menggunakan family folder dalam pengawasan menelan obat pada penderita TB paru di wilayah kerja Puskesmas Parigi Kabupaten Gowa. Jurnal Kesehatan Yamasi Makassar, 4(1), 98–110.

van Lieshout Titan, A., et al. (2024). Cost-effectiveness and health impact of screening and treatment of M. tuberculosis infection among formerly incarcerated individuals. The Lancet Global Health. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2824%2900221-3/fulltext

World Health Organization & Pemerintah Indonesia. (2025). Strengthening TB surveillance to accelerate Indonesia’s path to elimination. World Health Organization. https://www.who.int/indonesia/news/detail/01-07-2025-strengthening-tb-surveillance-to-accelerate-indonesia-s-path-to-elimination

Downloads

Published

2025-10-04

How to Cite

Ira Widya Sari, Yani Pratiwi, Irfan Kurniawan, & A.Aulia Salsabila. (2025). Cost Effectivie Analysis (CEA) Pengobatan Tunggal dan Kombinasi pada Pasien Tuberkulosis Paru di RSUD dr. La Palaloi Kabupaten Maros . Jurnal Kesehatan Amanah, 9(2), 429–440. https://doi.org/10.57214/jka.v9i2.976

Issue

Vol. 9 No. 2 (2025): Jurnal Kesehatan Amanah

Section

Articles

License

Copyright (c) 2025 Jurnal Kesehatan Amanah

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.